Literature DB >> 27073468

Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.

Meng-Hua Dong1, Qian Zhang1, Yuan-Yuan Wang2, Bai-Sui Zhou3, Yu-Fei Sun1, Qiang Fu1.   

Abstract

Euphorbia fischeriana Steud, a traditional Chinese medicine, has been shown to inhibit the growth of various cancers by the induction of apoptosis and cell cycle arrest. The purpose of the present study was to investigate the association between the phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and the inhibitory effect of Euphorbia fischeriana Steud on the growth and metastasis of melanoma B16 cells in vitro, and the underlying mechanisms. MTT assay results indicated that Euphorbia fischeriana Steud inhibited the growth of B16 cells in a time- and dose-dependent manner. Flow cytometric analysis revealed that Euphorbia fischeriana Steud markedly induced apoptosis of the B16 cells, with arrest at the G0/G1 phase of the cell cycle. In addition, in a Transwell assay Euphorbia fischeriana Steud significantly suppressed the migration of B16 cells. Western blot analysis revealed that the expression levels of phosphatase and tensin homolog (PTEN) were upregulated, and the phosphorylation of Akt was downregulated, which resulted in inhibition of the PI3K/Akt signaling pathway and the eventual suppression of its downstream targets, such as matrix metalloproteinase-2 mRNA, in B16 cells. The results demonstrated that Euphorbia fischeriana Steud inhibited the growth and migration of B16 cells, possibly via modulation of the PI3K/Akt signaling pathway and upregulation of PTEN expression levels, in addition to downregulation of p-Akt expression. The aforementioned findings suggest that Euphorbia fischeriana Steud may have broad therapeutic applications in the treatment of malignant melanoma.

Entities:  

Keywords:  Euphorbia fischeriana Steud; PI3K/Akt signaling pathway; malignant melanoma; traditional Chinese medicine

Year:  2016        PMID: 27073468      PMCID: PMC4812171          DOI: 10.3892/etm.2016.3061

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  35 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 3.  Vaccines for melanoma and renal cell carcinoma.

Authors:  Howard L Kaufman
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 4.  Chemical constituents and biological activities of Euphorbia fischeriana Steud.

Authors:  Yong-Xu Sun; Ji-Cheng Liu
Journal:  Chem Biodivers       Date:  2011-07       Impact factor: 2.408

Review 5.  The role of the PI3K-AKT pathway in melanoma.

Authors:  Michael A Davies
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 6.  The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Authors:  Friedegund Meier; Birgit Schittek; Silke Busch; Claus Garbe; Keiran Smalley; Kapaettu Satyamoorthy; Gang Li; Meenhard Herlyn
Journal:  Front Biosci       Date:  2005-09-01

Review 7.  The current state of targeted therapy in melanoma: this time it's personal.

Authors:  Keiran S M Smalley; Grant A McArthur
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

Review 8.  PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Authors:  Lise Willems; Jerome Tamburini; Nicolas Chapuis; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 9.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

Review 10.  Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future.

Authors:  A J Stratigos; A M Forsea; R J T van der Leest; E de Vries; E Nagore; J-L Bulliard; M Trakatelli; J Paoli; K Peris; J Hercogova; M Bylaite; T Maselis; O Correia; V Del Marmol
Journal:  Br J Dermatol       Date:  2012-08       Impact factor: 9.302

View more
  3 in total

1.  Jolkinolide A and Jolkinolide B Inhibit Proliferation of A549 Cells and Activity of Human Umbilical Vein Endothelial Cells.

Authors:  Lei Shen; Shan-Qiang Zhang; Lei Liu; Yu Sun; Yu-Xuan Wu; Li-Ping Xie; Ji-Cheng Liu
Journal:  Med Sci Monit       Date:  2017-01-14

2.  Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.

Authors:  Ming Bai; Mingzi Zhang; Fei Long; Nanze Yu; Ang Zeng; Ru Zhao
Journal:  Oncol Rep       Date:  2017-03-30       Impact factor: 3.906

Review 3.  Anti-Cancer Activities of Diterpenoids Derived from Euphorbia fischeriana Steud.

Authors:  Baiyu Jian; Hao Zhang; Cuicui Han; Jicheng Liu
Journal:  Molecules       Date:  2018-02-11       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.